China's Changing Drug Market In The Wake Of Essential Drugs List
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - As an important part of China's $850 billion healthcare reform plan, the Essential Drug List system will bring new challenges as well as opportunities for all players in China's drug supply chain